Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus

Sponsor

National University of Malaysia (Other)

Overall Status

Completed

CT.gov ID

NCT05290506

Collaborator

(none)

Enrollment

Location

Arms

Actual Duration (Months)

7.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

There are studies that suggest glycemic response to incretin-based therapies differs between Asians and Caucasians, whereby Asians have better response compared to Caucasians. Hence, the therapeutic response could also be augmented by difference in incretin system among various ethnicities. This study is carried out to study the effect of dipeptidyl-peptidase IV (DPPIV) inhibitors in prediabetes and T2DM patients who have different levels of GLP-1 and to determine the effect on glycemic profiles, insulin resistance/sensitivity, beta-cell functon.

Condition or Disease	Intervention/Treatment	Phase
PreDiabetes Type 2 Diabetes	Drug: Dipeptidyl-Peptidase IV Inhibitors	Phase 3

Detailed Description

A 12-week, open-label, single treatment study using linagliptin is conducted in 28 prediabetes and 22 T2DM subjects who are divided into low and high fasting GLP-1 groups. Prediabetes are recruited from OGTT screening. Type 2 diabetes patients are recruited from specialised diabetes clinic and routine follow-up. A 75-g oral glucose tolerance test (OGTT) is performed at week 0 and 12. Venous blood samples were drawn at times 0 (before initiation of OGTT), 30, 60, 90, 120 min from the indwelling catheter for measurement of glucose and insulin.All prediabetes and T2DM subjects receive Linagliptin 5mg once daily for a duration of 12 weeks.

Study Design

Study Type:

Interventional

Actual Enrollment :

50 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Intervention Model Description:

open-labelled, single treatment study between Low GLP-1 group and High GLP-1 group of prediabetes/type 2 diabetesopen-labelled, single treatment study between Low GLP-1 group and High GLP-1 group of prediabetes/type 2 diabetes

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Association of Fasting GLP-1 Level With the Effect of Linagliptin After an Oral Glucose Tolerance Test in Prediabetes and Type 2 Diabetes Mellitus

Actual Study Start Date :

Aug 1, 2020

Actual Primary Completion Date :

Mar 1, 2021

Actual Study Completion Date :

Mar 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Prediabetes Low GLP-1 prediabetes patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.	Drug: Dipeptidyl-Peptidase IV Inhibitors All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12 Other Names: linagliptin
Active Comparator: Prediabetes High GLP-1 prediabetes patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.	Drug: Dipeptidyl-Peptidase IV Inhibitors All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12 Other Names: linagliptin
Active Comparator: Diabetes Low GLP-1 type 2 diabetes mellitus patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.	Drug: Dipeptidyl-Peptidase IV Inhibitors All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12 Other Names: linagliptin
Active Comparator: Diabetes High GLP-1 type 2 diabetes mellitus patients were divided into high GLP-1 and low GLP-1 groups based on the median of fasting GLP-1 level. linagliptin 5mg once daily was administered.	Drug: Dipeptidyl-Peptidase IV Inhibitors All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12 Other Names: linagliptin

Outcome Measures

Primary Outcome Measures

change from baseline in glucose after 12-week treatment [baseline to 12 weeks]
OGTT is performed at week 0 (baseline) and 12 (complete treatment). plasma glucose levels are taken at time 0,30,60,90,120 minutes during OGTT.
change from baseline in HbA1c after 12-week treatment [baseline to 12 weeks]
plasma level of fasting HbA1c is taken at week 0 and 12 of study before OGTT
change from baseline in insulin sensitivity/resistance index after 12-week treatment [baseline to 12 weeks]
OGTT is performed at week 0 (baseline) and 12. Plasma levels of glucose and insulin are taken at time 0,30,60,90,120 min during the OGTT. HOMA-IR, HOMA-IS are used to measure insulin resistance and insulin sensitivity at week 0 and week 12

Secondary Outcome Measures

change from baseline in beta-cell function after 12-week treatment [baseline to 12 weeks]
OGTT is performed at week 0 (baseline) and 12 (treatment complete). HOMS-beta, insulinogenic index, oral disposition index are used to measure beta-cell funciton at week 0 and 12

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Prediabetes diagnosed from OGTT and T2DM subjects
HbA1c > 6.5% and <10%
Subjects not receiving any glucose-lowering medication or just receiving metformin and/or sulphonylureas and/or alpha-glucosidase inhibitors on stable dose for at least 3 months.
Subjects who are willing to participate and sign the informed consent form

Exclusion Criteria:

Subjects with ketoacidosis or lactic acidosis, overt diabetes, another disease causing secondary glucose intolerance, congestive heart failure (New York Heart Association Class III or IV), myocardial infarction, stroke or ischemic attacks in past 6 months, uncontrolled severe hypertension, active liver conditions such as cirrhosis or hepatitis [elevation in liver enzymes to higher activities than double the respective normal value], moderate to severe renal insufficiency, pregnancy, breast-feeding
Patients receiving insulin, GLP-1 receptor agonists, dipeptidyl peptidase IV inhibitors or glucose-lowering medications other than metformin /sulphonylureas /alpha-glucosidase inhibitors as treatment.
Subjects with uncontrolled blood glucose HbA1c>10%
Subjects who plan to move out of state / country